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m2 and oxaliplatin 130 mg/m2 on day 1, and S-1 40 mg/m2 twice a
day on days 1–14 of every 21-day cycle. This regimen seems to
have promising preliminary activity.
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Background: Currently, the role of A20 binding and inhibitor of
NF-kappaB (ABIN-1) in the development of non-small-cell lung
cancer remains unknown. This retrospective study investigated
expression of ABIN-1 and the association with prognosis in
patients with NSCLC after lung resection.
Methods: Quantitative real-time reverse transcriptase (RT)-PCR,
and Western blot analyses were used to detect expression of ABIN-
1 in 30 samples of NSCLC tissue and paracarcinomatous lung tis-
sue (PCLT), and in four samples of normal lung tissue. In addition,
immunohistochemical analysis was done for 80 NSCLC speci-
mens, and follow-up data from these patients were reviewed.
Findings: Both mRNA and protein expression of ABIN-1 were
significantly raised in NSCLC tissues compared with normal lung
tissues. Patients with NSCLC who had high ABIN-1 expression
had shorter overall survival than patients who had low ABIN-1
expression.
Interpretation: The current data revealed that increased expres-
sion of ABIN-1 was correlated with survival in patients with
NSCLC, indicating that ABIN-1 is a novel prognostic marker for
NSCLC.
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Background: Transitional-cell carcinoma (TCC) of the urinary
bladder is reported as the eighth most common malignancy and
the fourth most common among men in Pakistan. This study
aimed to assess the clinicopathological pattern, p53 status, and
stage distribution of TCC, and to classify bladder carcinomas pre-
senting among the population of central Punjab, including factory
workers, according to the revised WHO/ISUP criteria.
Methods: 145 patients, including 52 factory workers (mean age
35.2 years), with newly diagnosed operable primary bladder car-
cinomas who underwent cystoscopy-associated transurethral
resection of bladder tumours from January, 2004, to July, 2006,
were included. Relevant clinical and laboratory data of these
patients, including age, sex, tumour location, and type of surgi-
cal procedure, were recorded in separate proformas. After confir-
mation of the diagnosis, the tumours were graded separately for
each group – first, according to WHO Classification 1972 as pap-
illoma, TCC grade I, II, and III, and later, according to WHO/ISUP
Consensus Classification 1998 as papilloma, papillary neoplasm
of low malignant potential (PNLMP), low-grade papillary carci-
noma (LGPC), and high-grade papillary carcinoma (HGPC).
Tumour staging was done according to TNM criteria of the
American Joint Commission on Cancer. All tissues were also
subjected to immunohistochemistry (IHC) with monoclonal
anti-P53 antibody. Patients were followed up for 3 years, from
hospital records until July, 2010. Data were entered and analysed
using SPSS 17.0.
Findings: About 80% of patients were men and 20% were
women (the male-to-female ratio was 5.3:1). Clinical history was
similar for both sexes, with most patients (74%) presenting with
haematuria with or without altered urinary habits. WHO grading
revealed 35.9% grade I, 25.4% grade II, and 38.6% of tumours as
grade III. ISUP classification revealed 19.2% PNULMP, 23.6% LGPC,
39.4% HGPC, 9.6% non-papillary urothelial carcinomas (NPUC),
and 7.9% as carcinoma in situ (CIS). Tumour staging depicted an
overall 11.5% of tumours with stage Ta and 31.5% with stage T3-
4. Among 71% invasive carcinomas, 16% were low-grade and
84% were high-grade carcinomas. Immunohistochemical staining
of histological tissue sections of 73% of CIS and 84.23% of TCCs
were p53 positive. 10.7% of grade I, 44.9% of grade II, and 92.1%
of grade III tumours were positive for p53. There were signifi-
cantly more p53-positive cases seen in grade II–III tumours than
in grade I tumours (p = 0.0036). Similarly, stage T2–T4 tumours
stained more frequently and stronger than stage T1 tumours
(p = 0.021). No significant association between p53 status and
post-operative prognosis was observed in the 3 years of follow-
up (p = 2.131).
Interpretation: Prolonged follow-up of patients with bladder
cancer may indicate an unfavourable prognostic factor linked to
histopathological findings, and the presence of p53 mutation,
which may also indicate development of aggressive growth char-
acteristics in TCCs.
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